Inovia

Inovia Bio positions itself as a "techbio partner" that pairs purpose-built software platforms with drug-development advisory work, with the stated aim of producing regulatory-grade evidence to support decisions on a drug asset. Its published capability set covers four areas: clinical development (moving from a target product profile to a full clinical development plan), strategic advisory (development, regulatory and commercial strategy), integrated evidence planning (delivery of an IEP or IEGP), and real world evidence, including identification of strategic and regulatory use cases for RWE.

The company describes three organising principles: scientific rigour (using and developing methods), strategic expertise delivered by operators rather than analysts, and technology intended to remove operational burden from drug development teams, with a stated position that AI is applied selectively rather than universally. Publicly stated delivery timelines include completing an entire IEP/IEGP in around 10 days, prioritising indications in under 20 days, moving from data to a publication-ready manuscript in hours, and augmenting clinical strategy with regulatory-grade evidence in days. The company also publishes written content on trial design and methodology topics such as the estimands framework, designing trials around an intended label, and analysing competitors' protocols.

Business model

Inovia Bio combines advisory services with proprietary software platforms delivered to drug development teams. It states that engagements do not involve change orders, indicating fixed-scope or fixed-fee commercial terms rather than variable billing.

Traction

The company publishes claimed delivery timelines for its services, including a 10-day integrated evidence plan and sub-20-day indication prioritisation, and maintains an ongoing series of insight posts.